Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Poly (ADP-Ribose) Polymerase Inhibitors - Pipeline Insight, 2021" drug pipelines have been added to ResearchAndMarkets.com's offering.

This "Poly (ADP-ribose) polymerase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly (ADP-ribose) polymerase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-ribose) polymerase inhibitors R&D. The therapies under development are focused on novel approaches for Poly (ADP-ribose) polymerase inhibitors.

Poly (ADP-ribose) polymerase inhibitors Emerging Drugs Chapters

This segment of the Poly (ADP-ribose) polymerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Poly (ADP-ribose) polymerase inhibitors Emerging Drugs

Talazoparib: Pfizer

Talazoparib is an investigational anticancer drug called a PARP (poly ADP ribose polymerase) inhibitor, which is being evaluated in breast cancer patients with germline BRCA (gBRCA) mutations, as well as other cancer types with deficiencies in DNA damage repair (DDR). Talazoparib has not been approved by any Regulatory Authorities for the treatment of any disease. As a dual-mechanism PARP inhibitor, talazoparib is believed to both inhibit and trap the PARP enzyme, which may lead to heightened cell death.

Niraparib: Janssen

Niraparib is an orally-administered selective PARP inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer.

In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer.

There are approx. 20+ key companies which are developing the Poly (ADP-ribose) polymerase inhibitors. The companies which have their Poly (ADP-ribose) polymerase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

Key Questions Answered

• How many companies are developing Poly (ADP-ribose) polymerase inhibitors drugs?
• How many Poly (ADP-ribose) polymerase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly (ADP-ribose) polymerase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly (ADP-ribose) polymerase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Poly (ADP-ribose) polymerase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Janssen
• Jiangsu HengRui Medicine
• Jeil Pharmaceutical
• Rhizen Pharmaceuticals
• Rakovina Therapeutics
• Ribon Therapeutics
• Cybrexa Therapeutics
• Waverley Pharma
• Idience
• IMPACT Therapeutics
• Cephalon
• Shanghai De Novo Pharmatech
• Clovis Oncology
• BeiGene
• Abbvie
• AstraZeneca
• NanoGhost
• Allarity Therapeutics

Key Products

• Talazoparib
• Niraparib
• Fluzoparib
• Olaparib
• Veliparib
• Amelparib
• RP 12146
• CK 102
• 2X-121
• Pamiparib
• NG 1002
• SC 10914
• Rucaparib

Research programme: monoPARP inhibitors

• CBX 11
• Senaparib
• Venadaparib

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/n6rfox